Pulmatrix: Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024

Pulmatrix: Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Press Release: Pulmatrix : SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pulmatrix, Inc. (PULM)

Pulmatrix: Plumatrix to merge with Cullgen Inc.

Pulmatrix: SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. - PULM

Pulmatrix, Inc.: Pulmatrix's revenue changed from $11.39M in Jun 2024 to $10.01M in Sep 2024

Pulmatrix: Pulmatrix GAAP EPS of -$1.59, revenue of $1.6M

Pulmatrix: MannKind acquires Pulmatrix R&D facility and the companies cross-license inhalation technology

Pulmatrix: Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

Pulmatrix: Pulmatrix : Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - Form 8-K